Piper Sandler lowered the firm’s price target on Idexx Laboratories (IDXX) to $750 from $775 and keeps a Neutral rating on the shares following quarterly results. The firm says its updated price target primarily reflects its updated multiple and rolling forward of estimates to 2027 from 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target lowered to $800 from $850 at Barclays
- Idexx Laboratories price target lowered to $730 from $750 at UBS
- Balanced Risk Profile and Slower Near-Term Margin Expansion Support Neutral Stance on Idexx Laboratories
- Idexx Laboratories: Strong Q4 Execution, Robust 2026 Outlook, and Expanding Diagnostics Platform Support Buy Rating
- Idexx Laboratories price target lowered to $800 from $830 at BTIG